Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial

Mihai Gheorghiade, Joseph S. Rossi, William Cotts, David D. Shin, Anne S. Hellkamp, Ileana L. Piña, Gregg C. Fonarow, Teresa DeMarco, Daniel F. Pauly, Joseph Rogers, Thomas G. DiSalvo, Javed Butler, Joshua M. Hare, Gary S. Francis, Wendy Gattis Stough, Christopher M. O'Connor

Research output: Contribution to journalArticlepeer-review

289 Scopus citations


Background: Mild hyponatremia is relatively common in patients hospitalized with heart failure (HF). To our knowledge, the association of hyponatremia with outcomes has not been evaluated in the context of in-hospital clinical course including central hemodynamics and changes in serum sodium level. Methods: The ESCAPE trial (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) was a randomized, controlled study designed to evaluate the utility of a pulmonary artery catheter plus clinical assessment vs clinical assessment alone in guiding therapy in patients hospitalized with New York Heart Association class IV HF due to systolic dysfunction (left ventricular ejection fraction <30%). A Cox proportional hazards model with baseline serum sodium level as a continuous variable was used to examine the association of serum sodium level with 6-month postdischarge mortality, HF rehospitalization, and death or rehospitalization. A categorical analysis was also performed comparing persistent and corrected hyponatremia. Results: A total of 433 hospitalized patients with HF were enrolled in ESCAPE. Hyponatremia (serum sodium level ≤134 mEq/L) was present in 103 patients (23.8%). (To convert serum sodium to millimoles per liter, multiply by 1.0.) Of these, 71 had persistent hyponatremia (68.9%). Hyponatremia was associated with higher 6-month mortality after covariate adjustment (hazard ratio [HR] for each 3-mEq/L decrease in sodium level, 1.23; 95% confidence interval [CI], 1.05-1.43) (P=.01). After controlling for baseline variables and clinical response, we found that patients with persistent hyponatremia had an increased risk of all-cause mortality (31% vs 16%; HR, 1.82) (P=.04), HF rehospitalization (62% vs 43%; HR, 1.52) (P=.03), and death or rehospitalization (73% vs 50%; HR, 1.54) (P=.01) compared with normonatremic patients. Conclusion: Persistent hyponatremia was an independent predictor of mortality, HF hospitalization, and death or rehospitalization despite clinical and hemodynamic improvements that were similar to those in patients without hyponatremia.

Original languageEnglish (US)
Pages (from-to)1998-2005
Number of pages8
JournalArchives of internal medicine
Issue number18
StatePublished - Oct 8 2007
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial'. Together they form a unique fingerprint.

Cite this